Tudriqev's US launch tests how payers treat accelerated-approval oncology products

What happened

Replimune said in its 28 October 2026 quarterly update that Tudriqev (vusolimogene oderparepvec-wtpg) became commercially available in the US in early October 2026. It is an oncolytic HSV-1 therapy given with nivolumab to adults with unresectable advanced cutaneous melanoma that progressed after PD-1 therapy.

The company also reported three access-relevant milestones. The product has been added to NCCN guidelines as a category 2A recommendation. Several payers have published coverage policies. The confirmatory Phase 3 IGNYTE-3 trial is enrolling. The update does not name the payers, describe their criteria or give any sales or patient figures, so the depth of early coverage cannot yet be judged.

Why the accelerated-approval basis matters

The indication was granted accelerated approval on response rate and duration of response. Under that pathway, continued approval can depend on confirmatory trial results. For market access teams, this makes Tudriqev's commercial position more conditional than that of a product approved on survival or other clinical-benefit endpoints.

Payers that have already published policies may reserve the right to revisit them as IGNYTE-3 matures. Teams modelling the product, or competing in post-PD-1 melanoma, should treat the confirmatory readout as a point at which coverage terms could change. The records give no timing for that readout, so it is not yet known.

The NCCN listing is a practical asset. Compendia and guideline recommendations often anchor payer decisions and appeals in US oncology. A category 2A recommendation is a consensus position based on lower-level evidence, which fits an accelerated-approval dataset. It supports coverage but does not replace confirmatory data.

Early-launch signals elsewhere in the market

Two other 28 October and 26 October updates show how early launch evidence is being reported. Citius Oncology released preliminary, unaudited figures for LYMPHIR (denileukin diftitox-cxdl), launched in December 2025 for relapsed or refractory Stage I-III cutaneous T-cell lymphoma. Wholesalers bought 792 units in the quarter ended 30 September 2026, up from 360 the previous quarter. Institutions that have ordered rose to 54 from 44 in mid-August. The company is aiming for formulary placement at 100 priority institutions by calendar year-end and plans to report full results in December 2026.

Those figures measure wholesaler purchasing and institutional ordering, not patient demand or reimbursement outcomes, and they are unaudited. Still, they show the metrics specialist oncology launches are judged on in their first year: institutional orders and formulary placement. Replimune's update leans on guideline and payer-policy milestones instead, so the two disclosures are not directly comparable.

Amarin offers a European contrast. Its partner Recordati launched icosapent ethyl (Vazkepa) privately paid, meaning non-reimbursed, in Poland in October while it pursues pricing and reimbursement elsewhere. Amarin says the product is now sold in 22 countries, 11 of them in Europe. Private-pay entry is one route to market while reimbursement is pending, but the records do not quantify its uptake.

The European and Italian backdrop

The records do not say whether Tudriqev is filed or under review in Europe, so no EU access conclusions can be drawn for it. Several 26-28 October items do show the environment European access teams are working in.

The European Commission (DG SANTE) updated its procedural guidance for HTA joint scientific consultations, covering medicinal products and medical devices/in-vitro diagnostics, to add the role of a 'watcher'. The source does not say who the watcher is or what the role involves, so developers should read the full guidance before planning consultation participation. DG SANTE also published a flash report of the 22 October 2026 HTACG meeting. The input gives no details of topics or decisions, so any implications for joint clinical assessments need checking in the full report.

In Italy, AIFA updated the Monitoring Registry for FABHALTA (iptacopan) in C3 glomerulopathy. It did not say what changed, so centres should check the registry for revised requirements. AIFA also published its Class A and Class H tables as of 30 June 2026, a reference for reimbursement and dispensing classification. These are routine but show that registry and classification administration remains part of market access in Italy.

What to watch

For Tudriqev, the main open questions are which payers have published policies, on what criteria, and how coverage will respond to IGNYTE-3 data. For LYMPHIR, the December 2026 full results will show whether the preliminary order trend holds. For HTA teams in Europe, the full texts of the JSC guidance and the HTACG flash report are the next reading.